Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
Top Cited Papers
- 1 June 2002
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 359 (9324) , 2131-2139
- https://doi.org/10.1016/s0140-6736(02)09088-8
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- The effect of anastrozole (Arimidex™) on serum lipids — a randomized comparison of Anastrozole (AN) vs Tamoxifen (TAM) in Postmenopausal women with Advanced Breast CancerEuropean Journal Of Cancer, 2001
- How are bisphosphonates used today in breast cancer clinical practice?Seminars in Oncology, 2001
- Risk and prognosis of endometrial cancer after tamoxifen for breast cancerThe Lancet, 2000
- Rheumatoid Symptoms Following Breast Cancer Treatment: A Controlled ComparisonJournal of Pain and Symptom Management, 1999
- Tamoxifen and risk of idiopathic venous thromboembolismBritish Journal of Clinical Pharmacology, 1998
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Randomized Trial of Two Versus Five Years of Adjuvant Tamoxifen for Postmenopausal Early Stage Breast CancerJNCI Journal of the National Cancer Institute, 1996
- Gynaecological monitoring during tamoxifen therapyThe Lancet, 1994
- A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive TumorsNew England Journal of Medicine, 1989
- TAMOXIFEN AND CONTRALATERAL BREAST CANCERThe Lancet, 1985